产科研究图景:2007-2020年临床试验横断面分析
该横断面研究分析ClinicalTrials.gov注册的干预性试验,比较产科与非产科试验的特征。产科试验仅占1.9%,年增长10.8%,但早期终止风险更高(aHR 1.40),结果报告率相似(aOR 0.89)。
要点
- 产科试验仅占全部干预性试验的1.9%,年增长率为10.8%。
- 产科试验早期终止风险显著高于非产科试验(aHR 1.40,95%CI 1.21-1.62)。
- 美国政府资助的产科试验早期终止风险最低(aHR 0.23),学术资助结果报告率最低(aOR 0.39)。
核心结论
- 产科试验仅占ClinicalTrials.gov全部临床试验的1.9%,且完成情况较差。
- 需要增加产科试验数量并改善其完成与结果传播,以反映产科疾病负担并推进孕产妇健康。
研究设计与样本
- 横断面研究,分析2007年10月1日至2020年3月9日注册于ClinicalTrials.gov的干预性试验。
- 共纳入4276项产科试验(1.9%)和219235项非产科试验(98.1%),采用描述性、logistic回归和Cox回归分析。
主要发现
- 产科试验数量随时间增加,年增长率为10.8%。
- 与非产科试验相比,产科试验早期终止风险更高(aHR 1.40,95%CI 1.21-1.62,P<.0001),结果报告率相似(aOR 0.89,95%CI 0.72-1.10,P=.19)。
- 在产科试验中,美国政府资助的试验早期终止风险最低(aHR 0.23,95%CI 0.07-0.69,P=.009;参照行业资助)。
- 学术资助的产科试验结果报告率最低(aOR 0.39,95%CI 0.22-0.68,P=.0009;参照行业资助)。
临床怎么用
- 临床医生和研究者应关注产科试验的高早期终止风险,优先选择政府资助等完成率较高的研究模式。
- 学术机构需改进产科试验的结果报告与传播,确保研究证据可及。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obstetrical complications affect more than a third of women globally, but are underrepresented in clinical research. Little is known about the comprehensive obstetrical clinical trial landscape, how it compares with other fields, or factors associated with the successful completion of obstetrical trials. OBJECTIVE: This study aimed to characterize obstetrical clinical trials registered on ClinicalTrials.gov with the primary objective of identifying features associated with early discontinuation and results reporting. STUDY DESIGN: This is a cross-sectional study with descriptive, logistic regression and Cox regression analyses of clinical trials registered on ClinicalTrials.gov. Our primary exposure variables were trial focus (obstetrical or nonobstetrical) and trial funding (industry, United States government, or academic). We conducted additional exploratory analyses of other trial features including design, enrollment, and therapeutic focus. We examined the associations of exposure variables and other trial features with 2 primary outcomes: early discontinuation and results reporting. RESULTS: We downloaded data for all studies (N=332,417) registered on ClinicalTrials.gov from October 1, 2007, to March 9, 2020, from the Aggregate Analysis of ClinicalTrials.gov database. We excluded studies with a noninterventional design (n=63,697) and those registered before October 1, 2007 (n=45,209). A total of 4276 obstetrical trials (1.9%) (ie, interventional studies) and 219,235 nonobstetric trials (98.1%) were compared. Among all trials, 2.8% of academic-funded trials, 1.9% of United States government-funded trials, and 0.4% of industry-funded trials focused on obstetrics. The quantity of obstetrical trials increased over time (10.8% annual growth rate). Compared with nonobstetrical trials, obstetrical trials had a greater risk of early discontinuation (adjusted hazard ratio, 1.40; 95% confidence interval, 1.21-1.62; P<.0001) and similar odds of results reporting (adjusted odds ratio, 0.89; 95% confidence interval, 0.72-1.10; P=.19). Among obstetrical trials funders after controlling for confounding variables, United States government-funded trials were at the lowest risk of early discontinuation (United States government, adjusted hazard ratio, 0.23; 95% confidence interval, 0.07-0.69; P=.009; industry reference; academic, adjusted hazard ratio, 1.04; 95% confidence interval, 0.62-1.74; P=.88). Academic-funded trials had the lowest odds of results reporting after controlling for confounding variables (academic institutions, adjusted odds ratio, 0.39; 95% confidence interval, 0.22-0.68; P=.0009; industry reference; United States government, adjusted odds ratio, 1.06; 95% confidence interval, 0.53-2.09; P=.87). CONCLUSION: Obstetrical trials represent only 1.9% of all clinical trials in ClinicalTrials.gov and have comparatively poor completion. All stakeholders should commit to increasing the number of obstetrical trials and improving their completion and dissemination to ensure clinical research reflects the obstetrical burden of disease and advances maternal health.
引用
- Steinberg JR, Weeks BT, Reyes GA, et al. The obstetrical research landscape: a cross-sectional analysis of clinical trials from 2007-2020. Am J Obstet Gynecol MFM. 2020. PMID: 33043288. doi:10.1016/j.ajogmf.2020.100253
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。